A worker sprays pollen fixatives on juniper trees in Beijing on Sunday. [Photo provided to China Daily] Beijing has rolled out a series of targeted measures to reduce airborne pollen levels this ...

MOH said it will provide an update when it is ready, with a decision expected to be made in 2026. Read more at straitstimes.com. Read more at straitstimes.com.

Lebrikizumab improved disease severity, skin clearance and symptom relief in children with moderate to severe atopic dermatitis, according to topline results from a phase 3 trial. “Dupilumab [Dupixent ...

If you suspect you’re experiencing an allergic reaction, contact your doctor immediately to discuss next steps. “If the itchiness is due to a mild allergy, an antihistamine may provide relief,” Ali ...

Health experts have warned that eyelash extensions - a popular beauty treatment used to lengthen and thicken natural lashes - ...

Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line ...

A honey bee sting can cause pain and inflammation. A top neurologist shares a complete guide on symptoms after a sting, ...

Mon, Mar 16, 2026 A young dad was left "screaming in agony" and "lost three years" of his life after suffering a severe ...

Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and good tolerability for up to 3 years in patients with ...